Osteoporosis: Treat-to-Target

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2017 Feb 26

PMID 28236035

Citations 8

Authors

E Michael Lewiecki

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Treat-to-target (goal-directed therapy) has been proposed as a strategy to assist clinicians in selecting the most appropriate initial treatment for osteoporosis and guiding subsequent decisions to continue, change, or stop treatment. This is a review of the current medical evidence regarding treatment targets and potential clinical applications in managing patients with osteoporosis.

Recent Findings: Analyses of randomized placebo-controlled trials of approved agents to treat osteoporosis have generally shown that larger increases in bone mineral density are associated with greater reduction in fracture risk. Achievement of T-scores > -2.5 to -2.0 with treatment appears to provide little additional fracture protection. The paradigm of treat-to-target is aimed at enhancing and individualizing the care of patients with osteoporosis. Based on the best available data, the most promising target is T-score > -2.5. More data are needed to validate the clinical utility of treat-to-target for osteoporosis.

Citing Articles

Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.

Baek H, Shin K, Kim J, Jeong C, Lee J, Lim Y J Bone Miner Metab. 2024; 42(6):720-727.

PMID: 39349870 DOI: 10.1007/s00774-024-01552-0.

Antiosteoporosis effect of bryodulcosigenin on ovariectomy-induced osteoporosis in experimental rats.

Sun K, Qin L Acta Cir Bras. 2024; 39:e391024.

PMID: 38656061 PMC: 11037890. DOI: 10.1590/acb391024.

Spinal Sagittal Imbalance is Associated with Vertebral Fracture without a Definite History of Falls: Cross-Sectional, Comparative Study of Cohort with and without a Distal Radius Fracture.

Lee J, Lee H, Gong H J Bone Metab. 2023; 30(4):339-346.

PMID: 38073267 PMC: 10721377. DOI: 10.11005/jbm.2023.30.4.339.

Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.

Yavropoulou M, Anastasilakis A, Tzoulis P, Tournis S, Rigatou E, Kassi E Acta Biomed. 2022; 93(5):e2022305.

PMID: 36300213 PMC: 9686151. DOI: 10.23750/abm.v93i5.13668.

Long-Term Treatment of Postmenopausal Osteoporosis.

Brown J Endocrinol Metab (Seoul). 2021; 36(3):544-552.

PMID: 34154042 PMC: 8258325. DOI: 10.3803/EnM.2021.301.

References

Lewiecki E, Lane N . Common mistakes in the clinical use of bone mineral density testing. Nat Clin Pract Rheumatol. 2008; 4(12):667-74. PMC: 3891842. DOI: 10.1038/ncprheum0928. View

Black D, Reid I, Boonen S, Bucci-Rechtweg C, Cauley J, Cosman F . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27(2):243-54. PMC: 3427916. DOI: 10.1002/jbmr.1494. View

Hochberg M, Ross P, Black D, Cummings S, Genant H, Nevitt M . Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999; 42(6):1246-54. DOI: 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U. View

Lewiecki E, Binkley N . What we don't know about osteoporosis. J Endocrinol Invest. 2016; 39(5):491-3. DOI: 10.1007/s40618-016-0442-8. View

Hochberg M, Greenspan S, Wasnich R, Miller P, Thompson D, Ross P . Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002; 87(4):1586-92. DOI: 10.1210/jcem.87.4.8415. View

Black D, Bauer D, Schwartz A, Cummings S, Rosen C . Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?. N Engl J Med. 2012; 366(22):2051-3. PMC: 4015798. DOI: 10.1056/NEJMp1202623. View

Leslie W, Majumdar S, Lix L, Morin S, Johansson H, Oden A . Can change in FRAX score be used to "treat to target"? A population‐based cohort study. J Bone Miner Res. 2014; 29(5):1074-80. DOI: 10.1002/jbmr.2151. View

Leslie W, Lix L, Johansson H, Oden A, McCloskey E, Kanis J . Does osteoporosis therapy invalidate FRAX for fracture prediction?. J Bone Miner Res. 2012; 27(6):1243-51. DOI: 10.1002/jbmr.1582. View

Ferrari S, Adachi J, Lippuner K, Zapalowski C, Miller P, Reginster J . Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int. 2015; 26(12):2763-71. PMC: 4656715. DOI: 10.1007/s00198-015-3179-x. View

10.

Austin M, Yang Y, Vittinghoff E, Adami S, Boonen S, Bauer D . Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2011; 27(3):687-93. PMC: 3415619. DOI: 10.1002/jbmr.1472. View

11.

Cosman F, Cauley J, Eastell R, Boonen S, Palermo L, Reid I . Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?. J Clin Endocrinol Metab. 2014; 99(12):4546-54. DOI: 10.1210/jc.2014-1971. View

12.

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

13.

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

14.

Chesnut 3rd C, Silverman S, Andriano K, Genant H, Gimona A, Harris S . A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109(4):267-76. DOI: 10.1016/s0002-9343(00)00490-3. View

15.

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

16.

Lewiecki E, Cummings S, Cosman F . Treat-to-target for osteoporosis: is now the time?. J Clin Endocrinol Metab. 2013; 98(3):946-53. DOI: 10.1210/jc.2012-3680. View

17.

Lewiecki E, Watts N . Assessing response to osteoporosis therapy. Osteoporos Int. 2008; 19(10):1363-8. DOI: 10.1007/s00198-008-0661-8. View

18.

Miller P . Underdiagnosis and Undertreatment of Osteoporosis: The Battle to Be Won. J Clin Endocrinol Metab. 2016; 101(3):852-9. DOI: 10.1210/jc.2015-3156. View

19.

Shepherd J, Schousboe J, Broy S, Engelke K, Leslie W . Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD. J Clin Densitom. 2015; 18(3):274-86. DOI: 10.1016/j.jocd.2015.06.013. View

20.

Lee J, Vasikaran S . Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med. 2012; 32(2):105-12. PMC: 3289774. DOI: 10.3343/alm.2012.32.2.105. View